With the pandemic still raging, pharma stocks have continued to be extremely popular among investors in 2021.
EuropeFX
Covid-19 continues to take center stage in 2021 despite the development and initial rollout of vaccines worldwide. However, the world is quickly coming to grips with the fact that multiple vaccines will be needed to inoculate enough of the population to effectively combat the virus.
In light of early setbacks and logistical challenges there remains a large demand for more vaccine doses as well as additional options to meet demand.
As such, pharma stocks have continued to be extremely popular among investors in 2021, with many analysts forecasting even more potential for companies.
This fact is not lost on EuropeFX, which has consistently listened its growing user base by expanding its suite of tradable instruments.
Ahead of the development of Covid-19 vaccines, EuropeFX last summer grew its offering to include the biggest pharma stocks. Once again, the company has opted to listen to its clients with the addition of three new pharma stocks.
More opportunities than ever before
Volumes of pharma stocks are still at record highs, attesting to their popularity in 2021. This has helped create attractive. opportunities for all kinds of investors.
In addition to its existing slate of pharma stocks, EuropeFX now has on offer three other leading Covid-19 vaccine companies. This includes the following:
BioNTech SE
NASDAQ:BNTX
BioNTech SE is a German biotechnology company based in Mainz. The company is best known for developing and manufacturing active immunotherapies for patient-specific approaches to the treatment of diseases. Together with Pfizer, the joint vaccine from BioNTech has already been distributed to millions worldwide.
CureVac
(NASDAQ: CVAC)
CureVac N.V. is a German biopharmaceutical company that is domiciled in the Netherlands and headquartered in Tübingen, Germany. The group is responsible for developing therapies based on messenger RNA. The company's focus is on developing vaccines for infectious diseases and drugs to treat for cancer and rare diseases.
Novavax
(NASDAQ: NVAX)
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. Vaccine trials for a Covid-19 treatment are still ongoing.
Risk Warning:CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 79.97% of retail investor accounts lose money when trading CFDs with this provider. The information contained in this market overview should in no way be construed as investment advice and/or as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is not necessarily real-time or error-free. The data and prices on the material are not necessarily provided by a market or exchange, but by market makers, so that prices may not be accurate and may differ from the actual price in a particular market, meaning that prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of future performance. EuropeFX, its affiliates, agents, directors or employees do not guarantee the accuracy or validity of any information or data provided and shall not be liable for any loss arising from any investment based thereon. Trading Forex/CFD's carries a high level of risk and may result in the loss of your entire investment. Forex/CFD's are leveraged products and therefore trading Forex/CFD's may not be suitable for all investors. It is recommended not to invest more money than you can afford to lose in order to avoid significant financial problems in case of losses. Please make sure that you define the maximum risk for yourself.
Covid-19 continues to take center stage in 2021 despite the development and initial rollout of vaccines worldwide. However, the world is quickly coming to grips with the fact that multiple vaccines will be needed to inoculate enough of the population to effectively combat the virus.
In light of early setbacks and logistical challenges there remains a large demand for more vaccine doses as well as additional options to meet demand.
As such, pharma stocks have continued to be extremely popular among investors in 2021, with many analysts forecasting even more potential for companies.
This fact is not lost on EuropeFX, which has consistently listened its growing user base by expanding its suite of tradable instruments.
Ahead of the development of Covid-19 vaccines, EuropeFX last summer grew its offering to include the biggest pharma stocks. Once again, the company has opted to listen to its clients with the addition of three new pharma stocks.
More opportunities than ever before
Volumes of pharma stocks are still at record highs, attesting to their popularity in 2021. This has helped create attractive. opportunities for all kinds of investors.
In addition to its existing slate of pharma stocks, EuropeFX now has on offer three other leading Covid-19 vaccine companies. This includes the following:
BioNTech SE
NASDAQ:BNTX
BioNTech SE is a German biotechnology company based in Mainz. The company is best known for developing and manufacturing active immunotherapies for patient-specific approaches to the treatment of diseases. Together with Pfizer, the joint vaccine from BioNTech has already been distributed to millions worldwide.
CureVac
(NASDAQ: CVAC)
CureVac N.V. is a German biopharmaceutical company that is domiciled in the Netherlands and headquartered in Tübingen, Germany. The group is responsible for developing therapies based on messenger RNA. The company's focus is on developing vaccines for infectious diseases and drugs to treat for cancer and rare diseases.
Novavax
(NASDAQ: NVAX)
Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. Vaccine trials for a Covid-19 treatment are still ongoing.
Risk Warning:CFDs are complex instruments and carry a high risk of losing money quickly due to leverage. 79.97% of retail investor accounts lose money when trading CFDs with this provider. The information contained in this market overview should in no way be construed as investment advice and/or as a proposal and/or request for trading activities and financial transactions. The data contained in this market overview is not necessarily real-time or error-free. The data and prices on the material are not necessarily provided by a market or exchange, but by market makers, so that prices may not be accurate and may differ from the actual price in a particular market, meaning that prices are indicative and not suitable for trading purposes. There is no guarantee and/or prediction of future performance. EuropeFX, its affiliates, agents, directors or employees do not guarantee the accuracy or validity of any information or data provided and shall not be liable for any loss arising from any investment based thereon. Trading Forex/CFD's carries a high level of risk and may result in the loss of your entire investment. Forex/CFD's are leveraged products and therefore trading Forex/CFD's may not be suitable for all investors. It is recommended not to invest more money than you can afford to lose in order to avoid significant financial problems in case of losses. Please make sure that you define the maximum risk for yourself.
XBO.com Partners with Bank Frick to Deliver Comprehensive Fiat On/Off-Ramp and Corporate Banking Services
Featured Videos
FM Daily Brief - 1 May 2026
FM Daily Brief - 1 May 2026
FM Daily Brief - 1 May 2026
FM Daily Brief - 1 May 2026
iForex's CEO tells Finance Magnates the cost of their IPO delay. Also ahead: the US prediction markets legal battle splits in two, and the FCA greenlights onchain funds. It's Friday, the first of May 2026. You're listening to the Finance Magnates Daily Brief.
iForex's CEO tells Finance Magnates the cost of their IPO delay. Also ahead: the US prediction markets legal battle splits in two, and the FCA greenlights onchain funds. It's Friday, the first of May 2026. You're listening to the Finance Magnates Daily Brief.
iForex's CEO tells Finance Magnates the cost of their IPO delay. Also ahead: the US prediction markets legal battle splits in two, and the FCA greenlights onchain funds. It's Friday, the first of May 2026. You're listening to the Finance Magnates Daily Brief.
iForex's CEO tells Finance Magnates the cost of their IPO delay. Also ahead: the US prediction markets legal battle splits in two, and the FCA greenlights onchain funds. It's Friday, the first of May 2026. You're listening to the Finance Magnates Daily Brief.
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
Not All Video Reviews Are Created Equal | Finance Magnates
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
We deliver fast, structured, neutral reviews covering regulation, platforms, leverage, payouts, and risk across brokers, prop firms, and fintech platforms.
Book your Finance Magnates video review: https://lnkd.in/dDubZJ2S
#FinanceMagnates #BrokerReview #PropTrading #Fintech #Forex #Crypto #CFD #TradingPlatforms #DigitalAssets
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
FM Daily Brief - 30 April 2026
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
iForex posts its first annual results as a listed broker. Also ahead: CFI Financial secures a Brazil license, and prediction markets have a big week, with new ETF launches and fresh Polymarket loss data. It's Thursday, the thirtieth of April 2026. You're listening to the Finance Magnates Daily Brief.
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
FM Daily Brief - 29 April 2026
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
XTB and Robinhood both post first-quarter earnings. But the numbers point in very different directions. Also ahead: Capital.com pushes into three new markets and signals a move into payments.
It's Wednesday, the 29th of April 2026. You're listening to the Finance Magnates Daily Brief.
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
FM Daily Brief - 28 April 2026
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.
Startrader posts three-point-one trillion dollars in first-quarter volume — up three hundred and forty percent from a year ago. Also ahead: Fintokei claims sub-second trader payouts, and eToro opens its premium subscription tier to all investors.